NEW YORK (GenomeWeb News) – Penn State Hershey Children's Hospital and Serametrix today announced a collaboration to develop a companion diagnostic test for predicting patient response to a novel immunotherapy for brain cancer.
The deal is part of the Pediatric Cancer Immunotherapy Program at the hospital, which provides therapies aimed at children with relapsed tumors. The hospital has novel immune-based therapies for pediatric patients with relapsed neuroblastoma and sarcoma, and as part of the collaboration Serametrix will analyze about 100 samples from patients enrolled in trials for the therapies during the next year, the partners said.
Financial and other terms of the deal were not disclosed.
Based in Carlsbad, Calif., Serametrix develops technologies to detect changes in serum for personalized medicine-based approaches. The firm said it has identified tumor antigen panels for predicting clinical response in cancer types, including melanoma, colorectal cancer, breast cancer, and glioblastoma.